Sillajen, Inc.
Clinical trials sponsored by Sillajen, Inc., explained in plain language.
-
Cancer-Killing virus plus immunotherapy shows promise in kidney cancer trial
Disease control CompletedThis study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…
Phase: PHASE1, PHASE2 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase: PHASE3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC